Rankings
▼
Calendar
RNAC Q2 2023 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
RNAC
Cartesian Therapeutics, Inc.
$218M
Q2 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
-86.6% YoY
Gross Profit
-$13M
-238.8% margin
Operating Income
-$19M
-355.1% margin
Net Income
-$11M
-216.9% margin
EPS (Diluted)
$-2.23
QoQ Revenue Growth
-11.6%
Cash Flow
Operating Cash Flow
-$10M
Free Cash Flow
-$10M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$140M
Total Liabilities
$74M
Stockholders' Equity
$65M
Cash & Equivalents
$112M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$39M
-86.6%
Gross Profit
-$13M
$39M
-132.3%
Operating Income
-$19M
$14M
-234.5%
Net Income
-$11M
$9M
-232.4%
← FY 2023
All Quarters
Q3 2023 →